Molecular imaging in MSK radiology: Where are we going?

Eur J Radiol. 2021 Jul:140:109737. doi: 10.1016/j.ejrad.2021.109737. Epub 2021 Apr 28.

Abstract

Musculoskeletal (MSK) pathologies are one of the leading causes of disability worldwide. However, treatment options and understanding of pathogenetic processes are still partially unclear, mainly due to a limited ability in early disease detection and response to therapy assessment. In this scenario, thanks to a strong technological advancement, structural imaging is currently established as the gold-standard of diagnosis in many MSK disorders but each single diagnostic modality (plain films, high-resolution ultrasound, computed tomography and magnetic resonance) still suffer by a low specificity regarding the characterization of inflammatory processes, the quantification of inflammatory activity levels, and the degree of response to therapy. To overcome these limitations, molecular imaging techniques may play a promising role. Starting from the strengths and weaknesses of structural anatomical imaging, the present narrative review aims to highlight the promising role of molecular imaging in the assessment of non-neoplastic MSK diseases with a special focus on its role to monitor treatment response.

Keywords: Magnetic resonance imaging; Molecular imaging; Musculoskeletal diseases; Positron Emission Tomography; Response assessment; Scintigraphy.

Publication types

  • Review

MeSH terms

  • Humans
  • Molecular Imaging
  • Radiography
  • Radiology*
  • Tomography, X-Ray Computed*
  • Ultrasonography